IL-11 and IL-11 receptor (R)α are induced by Th2 cytokines. However, the role(s) of endogenous IL-11 in antigen-induced Th2 inflammation has not been fully defined. We hypothesized that IL-11, signaling via IL-11Rα plays an important role in aeroallergen-induced Th2 inflammation and mucus metaplasia. To test this hypothesis, we compared the responses induced by the aeroallergen ovalbumin (OVA) in wild type (WT) and IL-11Rα null mutant mice. We also generated and defined the effects of an antagonistic IL-11 mutein on pulmonary Th2 responses. Increased levels of IgE, eosinophilic tissue and bronchoalveolar lavage (BAL) inflammation, IL-13 production and increased mucus production and secretion were noted in OVA-sensitized and challenged WT mice.
INTRODUCTION
Asthma is a chronic disorder of the airway in which a Th2-dominated inflammatory response and subsequent airway remodeling are felt to play mechanistically important roles (1) (2) (3) (4) . In keeping with their importance, the cytokines that mediate these responses have been subject to significant investigation. These studies demonstrated that IL-4 plays a key role in Th2 cell differentiation (5) . In contrast, IL-13 is now believed to be the major effector of Th2 inflammation and tissue remodeling (4, 6) . Studies from our laboratory and others have also defined many of the pathways that are used to induce these alterations. As a result, it is now known that chemokines, matrix metalloproteinases (MMPs), TGF-β and chitinases contribute to the pathogenesis of pulmonary Th2 inflammation and remodeling (4, 7, 8) . However, the importance of IL-6 type cytokines in the generation of OVA-or IL-13-induced inflammation or tissue responses has not been fully defined.
IL-11 is a multifunctional IL-6-type cytokine that stimulates hematopoiesis, thrombopoiesis and megakaryocytopoiesis, enhances bone marrow resorption, regulates macrophage differentiation and confers mucosal protection after chemotherapy and radiation therapy (9) (10) (11) (12) .
Previous studies from our laboratory demonstrated that epithelial cells, fibroblasts and airway smooth muscle cells produce IL-11 in response to TGF-β 1 , IL-1, histamine, eosinophil major basic protein and specific respiratory viruses (10, (13) (14) (15) (16) (17) (18) and that the transgenic overexpression of IL-11 causes asthma-like airway fibrosis, myocyte hyperplasia and airways hyperresponsiveness on methacholine challenge (19, 20) . Our studies also demonstrated that IL-11 can be detected in exaggerated quantities in the nasal secretions of children with viral upper respiratory tract infections (16) and the airways of patients with asthma (21, 22) . However, the role of endogenous IL-11 and IL-11 signaling in the pathogenesis of Th2 inflammation has not been adequately defined. .
To define the role(s) of endogenous IL-11 in antigen-induced Th2 inflammation, we compared the acute responses induced by the aeroallergen ovalbumin (OVA) in wild type (WT) and IL-11Rα null mutant mice. We also generated and evaluated the effects of an antagonistic IL-11 mutein, on OVA-induced Th2 inflammation and IL-13-induced tissue responses. These studies demonstrate that the IL-11 pathway plays an important role in antigen sensitization and the eosinophilic inflammation, mucus metaplasia and IL-13 elaboration that are characteristic of pulmonary Th2 responses. They also demonstrate that IL-11 signaling contributes to the effector functions of IL-13 in the murine lung.
MATERIALS AND METHODS
Genetically Modified Mice.
IL-11Rα
−/− mice were provided by Drs. Lorraine Robb and C. Glenn Begley (The Walter and Eliza Hall Institute, Victoria Australia) (23) . These mice were bred for >10 generations onto a C57BL/6 genetic background. C57BL/6 WT controls were obtained from the Jackson Labs (Bar Harbor, ME, USA). CC10-rtTA-IL-13 transgenic mice were generated in our laboratory, bred onto a C57BL/6 background and used in these studies. These mice utilize the Clara cell 10 kDa protein (CC10) promoter and the reverse tetracycline transactivator (rtTA) to target IL-13 to the lung in a doxycycline inducible manner. The methods that were used to generate and characterize these mice were described previously (24) .
OVA Sensitization and Challenge
OVA sensitization and challenge were accomplished using a modification of the protocols previously described by our laboratory (23) . In brief, 6-to 8 wk old IL-11Rα null mutant mice and control littermates received injections containing 20µg of chicken OVA (Sigma, St. Louis, MO) complexed to alum (Resorptar, Indergen, New York, NY) or alum alone. This process was repeated 5 days later. After an additional 7 days, the animals received 3 aerosol challenges (40 min a day, 3 days) with 1% OVA (w/v) in endotoxin-free PBS or PBS alone. The aerosol was generated in a NE-U07 ultrasonic nebulizer (Omron Health care, Vernon Hills, IL). The mice were sacrificed 24, 48 or 72 h after aerosol exposure.
BAL and Lung Inflammation
Lung inflammation was assessed by BAL as described previously (23) . In brief, animals were anesthetized, a median sternotomy was performed, the trachea is dissected free from the underlying soft tissues, and BAL was performed by perfusing the lungs in situ with 0.8ml of PBS and gently aspirating the fluid back. This was repeated twice. The samples were then pooled and centrifuged, and cell numbers and differentials were assessed. The cell-free BAL fluid was stored at -70 °C until used.
Histologic Analysis
The lungs were removed en bloc as described above, inflated at 25cm pressure with PBS containing 0.5% low melting point agarose gel, fixed in Streck solution (Streck Laboratories, La Vista, NE), embedded in paraffin, sectioned and stained. Hematoxylin and eosin, and diastase- Histologic mucus index was estimated by the D-PAS stains as previously described (25) and tissue infiltration of the eosinophils was evaluated by Congo Red stains.
FACS Analysis
Cells from BAL fluids and lungs cell digests were subjected to the FACS analysis. BAL was performed as described previously. Whole lung cell suspensions were obtained by a modified method according to Rice WR et al (26) . In brief, lung tissue was digested using dispase (5 mg/ml, Stem Cell Technologies, Vancouver, Canada), collagenase (0.04%; Sigma-Aldrich, St. Louise, MO) and 100U/ml DNAse I (Sigma-Aldrich). After several centrifugations (10 min, 300g-1000g) and hemolysis (precooled hemolysis solution containing 11mM KHCO 3 , 152mM NH 4 Cl; washing 
Analysis of Mucus and Mucin Gene Expression
To quantitate the levels of Muc5ac, the major airway mucus in the BAL fluids, 0.1 ml of BAL fluid was slot blotted onto nitrocellulose membranes using a Minifold II slot blot apparatus (Schleicher & Schuell) according to the protocol provided by the manufacturer. After air-drying, the membrane was blocked with 5% skim milk in TTBS (0.1% Tween 20, 20 mM Tris-Cl, 500 mM NaCl) for 2 h and washed three times with TTBS. The membranes were then incubated overnight at 4°C with a monoclonal antibody against Mucin-5AC (45M1; NeoMarkers, Union City, CA). After washing with TTBS, the membranes were incubated for 1 h at room temperature with horseradish peroxidase-conjugated anti-mouse immunoglobulin (Ig)-G (Pierce).
Immunoreactive mucins were detected using a chemiluminescent procedure (ECL Plus Western blotting detection system, Amersham Biosciences) according to instructions from the manufacturer. The relative density was quantitated using an AlphaImager 2000 Image analyzing system (Alpha Innotech, San Leandro, CA). The levels of Muc5ac mRNA were evaluated via real time RT-PCR using Muc5ac specific primers (25) and a 7500 real-time PCR machine (Applied Biosystems Inc., Foster City, CA).
Generation of IL-11 Specific Antagonist Mutein
To further demonstrate the specific role of IL-11 signaling in our assay system, we generated IL-11 antagonist mutein that can specifically inhibit the binding of IL-11 to IL-11Rα. The proposed binding sites of the antagonist to inhibit the interaction between IL-11 and IL11-Rα are schematically illustrated in Online Supplemental Figure S1A . After screening a number of antagonistic variants from multiple phage libraries, several clones demonstrating highest affinities were selected through evaluation of binding affinity and dose-dependent kinetics of the antagonist using competition ELISA and Ba/F3 cell proliferation assay (Online Supplemental Figure S1 , B-D). A clone 1.21 was found to bind 20-fold higher affinity relative to the established reference of W147A IL-11 (27) . After site-specific polyethyleneglycosylation (PEGylation) of this clone to increase its in vivo half life, it was produced in a large quantities, shown to be endotoxin free in the Limulus assay and used to inhibit IL-11 signaling in these studies.
In vivo Mutein Treatment
To inhibit IL-11 signaling in the OVA aeroallergen model, mice received OVA plus alum as noted above. The mutein (500 µg per mouse/day) was administrated via intra-peritoneal (I.P.) injection at the time of the aerosol OVA challenge. In the experiments with the CC10-rtTA-IL-13 transgenic mice, mutein (500 µg/mouse/day) was administered starting one day before transgene induction with doxycycline (Dox).
Serum Total IgE and OVA-specific IgE Measurements
The levels of total and OVA-specific IgE in the serum were measured by ELISA using BD OptEIA kit (BD Bioscience) according to the manufacturer's protocol with modification (28).
In brief, ninety-six-well plates were coated with purified anti-mouse IgE mAb (clone R35-72: BD Bioscience) and a purified mouse IgE isotype (27-25: BD Bioscience) was used as a standard.
HRP-conjugated anti-mouse IgE (23G3: Southern Biotechnology, Birmingham, AL) (for total IgE) and HRP-labeled anti-biotin (Vector Laboratories, Barlingame, CA) following biotin-labeled OVA (for OVA-specific IgE) (kindly provided by Dr. Lauren Cohn, Pulmonary and Critical Care Medicine, Yale University) were added to the plates as detection enzymes. Pooled sera with known concentrations of IgE (5000pg/ml) were also obtained from Dr. Cohn and used as OVAspecific IgE standards. After adding HRP-substrate chromogen 3,3',5,5'-tetramethylbenzidine, the reaction was terminated and detected with a UV spectrometer.
Cytokine Measurements
The levels of IL-13 and other Th2 cytokines in BAL fluids were evaluated by ELISA using commercial assays (R&D Systems Inc., Minneapolis, MN) as described by the manufacturer.
Statistics
Normally distributed data are expressed as the mean ± SEM and assessed for significance by Student's t test or ANOVA as appropriate.
RESULTS

Role of IL-11α in OVA-induced Inflammation
To address the importance of IL-11 signaling in Th2 inflammation, we compared the OVAinduced tissue and BAL inflammatory responses in WT and IL-11Rα null mutant (IL-11Rα -/-) mice. In the WT mice OVA sensitization and challenge caused an increase in BAL cellularity and a comparable increase in tissue inflammatory cell accumulation ( Figure 1A and data not shown).
In both compartments, increases in eosinophils and macrophages were readily appreciated. ( Figure   1A and data not shown). Comparable levels of BAL and tissue inflammation were not seen in animals that were not sensitized before aeroallergen challenge or that received systemic Role of IL-11α in Aeroallergen Sensitization.
Because IL-11 signaling played a critical role in OVA-induced inflammation and mucus metaplasia, studies were next undertaken to determine if it also contributed to antigen sensitization. This was accomplished by comparing the levels of total and antigen-specific IgE in WT and IL-11Rα -/-mice after treatment with OVA plus alum. In these experiments significant increases in the levels of total and antigen-specific IgE were seen in WT mice (Figure 3 ). In contrast, both of these responses were significantly decreased in mice that were deficient in IL-11Rα -/- (Figure 3 ). These studies demonstrate that endogenous IL-11 signaling is essential for the optimal aeroallergen-induced sensitization. (data not shown). These data demonstrate that IL-11Rα plays a critical role in OVA-induced Th2 cytokine induction.
Effects of Mutein on OVA-induced Th2 Inflammation
The studies noted above demonstrate that IL-11 signaling plays a critical role in antigen sensitization, Th2 inflammation, mucus metaplasia and Th2 cytokine elaboration. The alterations that are seen in the absence of IL-11Rα could be entirely due to the defect in sensitization.
Alternatively, they could be due to defects in sensitization and defects in Th2 effector responses.
To differentiate amongst these options we characterized the ability of the IL-11 mutein to alter Th2 responses in OVA sensitized and challenged WT mice. This was done by administering the mutein or its polyethylene glycol (PEG) control at the time of OVA aerosol challenge. In these experiments OVA sensitization and challenge increased total BAL cell recovery by 5-6 fold in mice that received the PEG control. In contrast, BAL cell recovery was significantly decreased in mice that received the IL-11 mutein ( Figure 5A ). In accord with our studies with the IL-11 Rα -/-mice, eosinophil recovery was significantly decreased in the mutein treated animals ( Figure 5A ).
FACS analysis of the BAL cells further demonstrated that OVA-induced Th2 cell (CD4+IL-4+), dendritic cell (CD11C+ MHCII+), and eosinophil (CCR3+CD16+) numbers were significantly reduced in the mutein treated versus the PEG control treated animals ( Figure 5B ). Interestingly, OVA-induced dendritic cell activation (CD86 expression) was also significantly reduced in the mutein treated mice compared to vehicle treated mice ( Figure 5C ).
Effects of Mutein on OVA-induced IL-13 and Mucin Gene Expression
We next compared the IL-13 production and mucin gene expression in OVA sensitized WT mice treated with PEG vehicle control or the IL-11 mutein. As noted above, OVA sensitization and challenge increased BAL IL-13 mRNA accumulation, the levels of BAL IL-13, and the levels of Muc5ac mRNA accumulation in the PEG control treated animals ( Figure 6 ). In all cases, these responses were significantly decreased in mice treated with the IL-11 mutein (Figure 6 ).
Effects of Mutein on IL-13-induced Tissue Phenotypes
To gain insight into the mechanism(s) by which the IL-11 mutein could alter OVA-induced Th2 responses we tested the hypothesis that IL-11 signaling contributes to the pathogenesis of IL-13-induced tissue alterations. This was done by comparing the tissue responses in CC10-rtTA-IL-13 transgenic mice treated with the PEG vehicle control or the IL-11 mutein. In keeping with our prior studies, transgenic IL-13 caused an eosinophilic inflammatory response, goblet cell hyperplasia and enhanced mucin gene expression (4) (Figure 7) . Importantly, comparisons of transgenic mice treated with the PEG vehicle control and the IL-11 mutein demonstrated that each of these responses was decreased in the mutein treated animals ( Figure 7 ). These studies demonstrate that IL-11 signaling plays an important role in the pathogenesis of IL-13 effector responses in the murine lung. DISCUSSION IL-11 was originally discovered as an IL-6-like molecule that stimulated the proliferation of IL-6-dependent plasmacytoid cells (29) . Subsequent studies have focused largely on the effects of exogenously administered rIL-11 and its role as a potential therapeutic agent. These studies demonstrated that IL-11 is an important regulator of platelet accumulation (30, 31) and confers cytoprotection, inhibits inflammation and diminishes cell death (32, 33) at sites of mucosal and tissue injury. As a result of these investigations, rIL-11 has been approved as a therapeutic agent to treat thrombocytopenia (34, 35) . It has also received significant attention as an agent that can prophylaxis against toxin-induced tissue injury (12, 36) and control pathologic inflammatory disorders (9, 37) . In contrast, the roles of endogenous IL-11 have not been as extensively investigated. Because IL-11 is known to be overexpressed at sites of Th2 inflammation (22, 38), we used genetically modified mice and developed a soluble mutein that antagonizes IL-11-IL-11Rα binding to characterize the roles of physiologic IL-11R signaling in the pathogenesis of these responses. These studies demonstrate that IL-11 signaling plays a critical role in allergeninduced sensitization, dendritic cell accumulation and activation and IgE production. They also demonstrated that this IL-11 pathway plays a critical role in the pathogenesis of Th2 inflammation, Th2 cytokine elaboration and mucus metaplasia. These studies suggest that interventions that control IL-11 signaling can play a useful role in the regulation of disorders characterized by excessive Th2 inflammation and tissue remodeling responses.
Airway inflammation and remodeling are characteristic features of the exaggerated Th2 responses seen in asthma and mechanistically-related disorders (3, 39) . A number of lines of investigation have demonstrated that IL-11 expression is characteristic of these responses. This includes studies demonstrating that exaggerated levels of IL-11 mRNA can be found in biopsies from asthmatics where they correlate with disease severity and reductions in FEV 1 (21) . It also includes murine investigations which demonstrated that IL-11 is induced during antigen-stimulated Th2 responses via a leukotriene-dependent mechanism (38) , that IL-11 signaling plays an important role in the pathogenesis of IL-13-induced tissue inflammation, fibrotic and mucus responses (22) and that the transgenic overexpression of IL-11 induces asthma-like T and B cellrich inflammation, airway fibrosis, myofibroblast accumulation and physiologic dysregulation (20) . Our present studies add to our understanding of the biology of IL-11 and the role that it plays in Th2 responses by demonstrating, for the first time, that endogenous IL-11 contributes to antigen-induced Th2 sensitization, inflammation and tissue remodeling and that administration of an IL-11 antagonist can ameliorate these effects. These studies suggest that IL-11 plays a key role in the pathogenic Th2 responses that are seen in diseases like asthma. However, it is important to point out that this may actually be only part of the effector profile of IL-11 in this setting. A number of studies have demonstrated that IL-11 also has potent anti-inflammatory effects, including the ability to inhibit nuclear factor-κB activation (36) and induce the production of the TNF-α antagonist, soluble TNF-α Receptor 1 (40) . In keeping with these inhibitory properties, previous studies from our laboratory demonstrated that exogenous IL-11 can also inhibit antigeninduced Th2 inflammation and endothelial VCAM-1 expression (23) . When these bodies of investigation are viewed in combination, it is clear that IL-11 has complex, context-specific effects on Th2 inflammation with the endogenous product mediating pro-inflammatory and remodeling effects, while the exogenous administration of high concentrations of this cytokine activates compensatory pathways that are designed to feedback and control the responses. In many ways these properties of IL-11 are analogous to findings with transforming growth factor (TGF)-β 1 and IL-6 which have similar bi-directional modulatory effects (41) (42) (43) (44) This is an intriguing analogy because IL-6 and IL-11 are closely related members of the IL-6 type cytokine gene family (44) and studies from our laboratory and others have demonstrated that IL-11 is potently induced by TGF-β 1 in a variety of cells and tissues (10, 17, 45, 46) .
Patients with asthma can experience bronchorrhea and their biopsies are characterized by goblet cell hyperplasia and mucus accumulation (47) . This mucus response is nicely modeled in the antigen sensitized and challenged murine lung and has been the topic of significant investigation. These studies have demonstrated that a number of pathways contribute to airway mucus metaplasia including the elaboration of Th2 cytokines such as IL-13 and the activation of the epidermal growth factor receptor (EGFR) (48) (49) (50) . Our studies demonstrate that IL-11 signaling also contributes to this important airway response because OVA and IL-13-induced mucus metaplasia were significantly decreased in IL-11Rα null mice and mice treated with the IL-11 mutein. This inhibition could be due to the important role that IL-11 signaling plays in the production of IL-13. It is important to point out, however, that direct IL-11-induced regulatory effects can not be ruled out because the related cytokine IL-6 has been shown to have strong mucus-inducing capacity in primary tracheobronchial epithelial cells (51) . Additional investigation will be required to differentiate amongst these mechanistic options.
IL-13 is a product of a gene on chromosome 5 at q31. Although it was initially felt to be an IL-4-like molecule, it is now known to be a power stimulator of eosinophilic inflammation, tissue fibrosis, mucus metaplasia, alveolar remodeling and airways hyperresponsiveness. It is also known to be dysregulated in, and to potentially contribute to, the pathogenesis of a variety of disorders including asthma, idiopathic pulmonary fibrosis, scleroderma, viral pneumonia, hepatic fibrosis, nodular sclerosing Hodgkin's disease and chronic obstructive pulmonary disease (3, 7, (52) (53) (54) (55) (56) . Previous studies from our laboratory demonstrated that IL-13 induced inflammatory and mucus responses are diminished in IL-11Rα null mice (22) . The present studies add to our understanding of the role of IL-11 in this setting by demonstrating that the tissue effects of IL-13 in mice with a normal IL-11 receptor complex by treatment with the IL-11 mutein. This observation demonstrates that interventions that abrogate IL-11-IL-11Rα binding can be used to control the tissue effects of IL-13 in the lung and potentially other organs. However, the mechanism underlying mutein regulation of IL-13-induced inflammation and mucus response still remains to be determined. No significant changes in the STAT (STAT1, STAT3, STAT6) phosphoryaltion or acidic mammalian chitinase (AMCase) expression between the IL-13 transgenic mice with and without mutein treatment were detected in the additional mechanistic studies (Chen and Lee, unpublished observation). STAT6 is well known to mediate IL-13 signaling, and AMCase plays an critical role in Th2-or IL-13-induced inflammation (8) . was also known to confer protective effects on epithelial and inflammatory cells via induction of antiapoptotic molecules such as A1(bfl1) or survivin (57, 58) , and apoptosis is an important mechanism in the resolution of inflammation and maintenance of homeostasis of airway epithelial cells (50, 59) . Thus, it is intriguing to speculate that the inhibition of IL-11 signaling by mutein enhances apoptosis of these cells, resulting in fewer inflammatory cells and mucus producing epithelial cells. To define the exact underlying regulatory mechanism of endogenous IL-11 signaling in allergic inflammation and mucus response, further comprehensive in vitro and in vivo mechanistic studies are warranted.
In summary, these studies demonstrate that endogenous IL-11 signaling plays an important role in the pathogenesis of Th2 antigen sensitization and the pathogenesis of Th2-induced and IL- 
